CAMKK2-regulated differences in cancer cell size and mTOR signaling (assessed by p-S6 IHC) combined with the sustained alterations in circulating insulin levels suggest that insulin mediates CAMKK2’s effects on cancer via control of systemic metabolism. This evidence concerns the gene CAMKK2 and cancer.